Exosome storage and handling is the part of the supply chain almost nobody asks about, and it is the part most likely to quietly change what ends up in the syringe. A vial can leave a cleanroom with a flawless certificate of analysis and arrive at a clinic days later carrying a meaningfully different particle population, because the numbers on that certificate describe the product at release, not the product after it has been frozen, shipped, stored, and thawed.
The evidence base on this is unusually good, which is worth saying plainly, because so much of the exosome field is not. A 2024 systematic review in Stem Cell Research and Therapy pooled 50 original studies that deliberately manipulated storage temperature, freezing rate, freeze-thaw cycling, and stabilizing additives, then measured what happened to extracellular vesicle concentration, size, morphology, cargo, and bioactivity. The findings are consistent enough to be actionable, and they are the closest thing the field currently has to a handling standard.
This article walks through what that literature actually shows, what it does not show, and the specific questions a practitioner or an informed patient can ask a supplier. If you are new to the underlying biology, our overview of exosomes and our complete guide to what exosomes are cover the fundamentals this article assumes.
Why Exosome Storage and Handling Is a Clinical Question
Exosomes are lipid bilayer vesicles roughly 30 to 150 nanometers across. Their proposed biological activity depends on that membrane staying intact and on the protein and RNA cargo inside staying where it belongs. Unlike a small molecule drug, which is a defined chemical structure that either is or is not present, an exosome preparation is a population of fragile nanoscale structures whose useful properties are structural as much as chemical.
That has a practical consequence. A product can pass an identity test while having lost a substantial fraction of the thing that identity test was standing in for. Particle counting instruments report particles. They do not report whether those particles are still intact vesicles, whether they have fused into larger aggregates, or whether their cargo has leaked. This is the same measurement gap we described in our article on the exosome certificate of analysis, except that here the gap opens up after release testing is finished and nobody is looking.
So exosome storage and handling is not a shipping department concern. It is the interval during which a characterized product becomes an uncharacterized one, unless the cold chain is designed to prevent exactly that.
What the Temperature Data Actually Show
The systematic review’s headline conclusion is that rapid freezing and a constant subzero temperature, optimally minus 80 degrees Celsius, preserve vesicle quantity and cargo better than the alternatives. That sounds obvious until you look at how much worse the alternatives are.
Refrigeration is a holding state, not storage
Storage at plus 4 degrees Celsius is where a lot of real-world handling error lives, because a refrigerator feels like a safe place to put a biologic. In the pooled studies, purified vesicles held in plain phosphate buffered saline at plus 4 degrees Celsius showed roughly a 50 percent decline in RNA content within one week. Cargo degradation at refrigerator temperature is fast, and it is invisible to anyone looking at the vial.
Refrigeration has a legitimate role for brief holding immediately before use. It is not a storage condition, and a product that has spent days at plus 4 degrees Celsius should not be assumed equivalent to the same product stored properly.
Minus 20 degrees is worse than most people assume
This is the finding most likely to surprise a clinic, because a standard laboratory or pharmacy freezer runs at roughly minus 20 degrees Celsius and looks, functionally, like cold storage. In the reviewed data, vesicles held at minus 20 degrees Celsius for up to 26 weeks showed losses reported as high as 90 percent, with notably poorer preservation of size distribution than matched samples held at minus 80 degrees Celsius.
The mechanism is ice. At minus 20 degrees Celsius the sample is not uniformly vitrified; ice crystal growth and shifting solute concentration continue to act on the membranes over time. Minus 80 degrees Celsius largely arrests that process. A freezer that is cold to the touch is not the same as a freezer that is cold enough.
Minus 80 degrees Celsius is the working reference standard
Across the included studies, minus 80 degrees Celsius consistently outperformed warmer conditions for particle concentration, size stability, and cargo retention. It is the condition against which everything else in this field is measured, and it is the condition a supplier should be able to document from final fill through to the moment the shipper leaves their facility.
One honest caveat from the review authors: even minus 80 degrees Celsius has not been well validated over multi-year horizons. The evidence supports it strongly for months. Claims about two-year or three-year shelf life at minus 80 degrees Celsius are extrapolation unless the specific product has stability data behind them.
Freeze-Thaw Cycles and the Damage You Cannot See
Repeated freezing and thawing is the single most avoidable form of handling damage, and the review is unambiguous about its effects. Multiple freeze-thaw cycles reduced particle concentration and RNA content, impaired bioactivity in functional assays, and increased vesicle size and aggregation. Electron microscopy in the underlying studies showed enlarged, fused, and deformed vesicles after substandard handling.
The aggregation point deserves emphasis because of how it interacts with quality control. When damaged vesicles fuse, the particle count can fall while the average measured size rises. Depending on the instrument and the specification, a heavily freeze-thawed sample can still land inside a nominal size range. The number looks acceptable; the population underneath it is not the one that was released.
Practically, this argues for single-use vials sized to the intended treatment rather than larger vials drawn from more than once, and for a documented policy on what happens to a partially used vial. It also argues for knowing whether a product was thawed and refrozen at any point in transit, which is a question a temperature logger can answer and an assumption cannot.
Buffer and Formulation Matter More Than Expected
Two findings in the review cut against the intuition that a biologic is just a biologic.
The first is that stabilizing additives change the outcome substantially. Trehalose, a disaccharide widely used as a cryoprotectant, helped maintain vesicle integrity across storage conditions in the included studies. Formulations combining human albumin and trehalose showed markedly better RNA preservation than plain buffer, including retention over far longer intervals than unformulated preparations managed.
The second is that purified vesicles suspended in simple buffer were generally less stable than vesicles left in their native biofluid. Purification is necessary for a defined product, but it strips away the protein and lipid environment that was incidentally protecting the vesicles. A purified product therefore has to have that protection engineered back in through formulation, or it will degrade faster than a cruder preparation would.
The takeaway for evaluating a supplier is that “our exosomes are stored at minus 80” is an incomplete answer. Stored in what is the other half of the question, and it is a formulation question that sits alongside the sourcing and manufacturing controls described on our quality and standards page.
Lyophilization and the Room-Temperature Question
Freeze-drying is the most interesting current attempt to solve the cold chain by removing it. If water is removed and the vesicles are held in a dry, stabilized solid, there is no ice to form and no thaw to survive, and the product can in principle ship and sit at ambient temperature.
The review found real support for this direction. Appropriately formulated dry-state preparations retained a large majority of their vesicle content over six months, and one microneedle-embedded preparation showed only about a 3 percent loss of bioactivity over 12 months at room temperature. Those are strong numbers.
They also come with qualifications that matter. The lyophilization results depend heavily on the specific excipient formulation, so results do not transfer between products. Some reported drawbacks include altered surface characteristics and modest cargo loss during the drying process itself. And a freeze-dried product introduces a new controlled step, reconstitution, which has its own handling requirements at the point of care.
Lyophilization is a legitimate and promising approach rather than a settled one. A room-temperature claim should be backed by that specific product’s stability data, not by the general observation that freeze-drying works.
What to Ask a Supplier About Exosome Storage and Handling
These are answerable questions. A supplier that cannot answer them is telling you something.
- What temperature is the product stored at from fill to shipment, and is that logged? Minus 80 degrees Celsius is the reference standard for a frozen liquid product.
- How does it ship, and how long does the shipper hold temperature? Dry ice with a validated hold time longer than the expected transit, not overnight coolers with gel packs.
- Is there a temperature excursion record in the box? A single-use logger costs very little and converts an assumption into a record.
- What is the formulation? Plain buffer behaves differently from a cryoprotectant-containing formulation, and the difference is not marginal.
- How many freeze-thaw cycles has this lot experienced? The correct answer for a properly designed single-use product is one, at the point of use.
- What is the post-thaw window, and what is it based on? A specific number of hours supported by data, not “use it soon.”
- Is there stability data at the claimed shelf life, or is the shelf life extrapolated? This distinction is frequently blurred.
- Does the certificate of analysis describe this lot or a representative lot? Lot-specific documentation is the standard. Our example certificate of analysis shows what lot-level reporting looks like in practice.
Practitioners evaluating suppliers across exosome, stem cell, and peptide products will find that handling discipline tends to travel together with the rest of a quality system. A company that logs its cold chain generally also does the other unglamorous things, and the reverse is reliably true as well.
What This Means for Patients
Two things, and it is important not to overstate either.
The first is that the storage literature describes measurable changes to vesicle preparations in laboratory assays. It does not demonstrate that a poorly stored product produces worse clinical outcomes, because for exosome therapies the clinical outcome data needed to make that comparison largely does not exist yet. The honest formulation is that inadequate handling degrades the product in ways that are well documented at the bench, and that receiving a degraded product is not what anyone intends, whatever the eventual clinical evidence shows.
The second is the regulatory position, which has not changed. No exosome product is approved by the FDA for the treatment of any disease or condition. Exosome preparations are not approved biologics, and any marketing that describes an exosome product as FDA approved is misrepresenting its regulatory status. Handling quality is a floor, not a substitute for evidence of benefit. A perfectly cold-chained product is still an investigational one.
What a patient can reasonably do is ask where the product came from, how it was stored, and whether the clinic can produce lot-specific documentation. Those questions are answerable, and the answers are informative. Our research page tracks the published evidence base as it develops, and our article on exosome therapy side effects covers the safety questions that sit alongside these handling questions.
Built for Practitioners Who Ask These Questions
OmniGenix supplies exosome, stem cell, and peptide products to licensed practitioners only, with lot-level documentation and cold chain controls you can review before you order.
Frequently Asked Questions
Do exosomes have to be frozen?
Liquid exosome preparations do, in practice. The pooled storage literature identifies minus 80 degrees Celsius as the condition that best preserves particle concentration, size distribution, and cargo. Refrigeration at plus 4 degrees Celsius is appropriate only for brief holding immediately before use, since RNA content in unformulated preparations declined roughly 50 percent within a week at that temperature. Freeze-dried preparations are the exception and can be stable at ambient temperature, but only where that specific product has stability data supporting the claim.
Is a minus 20 degree freezer good enough for exosome storage?
The evidence says no. Studies comparing matched samples found substantially greater loss at minus 20 degrees Celsius than at minus 80 degrees Celsius over the same interval, with reported losses as high as 90 percent at 26 weeks and poorer preservation of size distribution. A standard pharmacy or laboratory freezer is not equivalent to ultra-low temperature storage, even though both are below freezing.
How many times can an exosome vial be thawed and refrozen?
Ideally once, at the point of use. Repeated freeze-thaw cycling reduced particle concentration and RNA content, impaired bioactivity, and increased vesicle aggregation across the reviewed studies. Because aggregation can raise average measured size while particle count falls, a heavily cycled sample may still fall inside a nominal specification while no longer matching the population that was released. Single-use vials sized to the intended treatment avoid the problem.
How can I tell whether a product was handled properly in transit?
Ask for the shipping method, the validated hold time of the shipper relative to actual transit time, and a temperature excursion record from the box. Single-use temperature loggers are inexpensive and turn cold chain integrity from a claim into a document. Also ask whether the certificate of analysis is lot-specific rather than representative, since lot-level documentation is the relevant standard.
The Short Version
Exosome storage and handling determines whether the product a clinician administers still resembles the product a laboratory characterized. The evidence is clearer here than in most areas of this field: rapid freezing, a constant minus 80 degrees Celsius, minimal freeze-thaw cycling, and a formulation designed to protect the vesicles rather than merely suspend them. None of that establishes clinical benefit, which remains unproven for exosome therapies generally. It establishes only that the product is what it was said to be, which is where any serious evaluation has to start.
For related background, see our comparison of exosomes and stem cells, our overview of stem cell products and peptide therapy, and our analysis of the wider exosome standardization problem that these handling questions sit inside.
Primary source: Ahmadian S, Jafari N, Tamadon A, Ghaffarzadeh A, Rahbarghazi R, Mahdipour M. Different storage and freezing protocols for extracellular vesicles: a systematic review. Stem Cell Research and Therapy. 2024;15(1):453. doi:10.1186/s13287-024-04005-7